SVA — Sinovac Biotech Income Statement
0.000.00%
Last trade - 00:00
HealthcareMicro Cap
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 230 | 246 | 511 | 19,375 | 1,493 |
Cost of Revenue | |||||
Gross Profit | 205 | 214 | 443 | 18,303 | 808 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 184 | 177 | 295 | 1,822 | 1,959 |
Operating Profit | 45.3 | 68.6 | 216 | 17,553 | -466 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 46.6 | 70.8 | 217 | 17,563 | 25.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | 36.1 | 65.2 | 185 | 14,459 | 88.1 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 21.8 | 44.9 | 110 | 8,467 | 114 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 21.8 | 39.8 | 104 | 8,461 | 108 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.336 | 0.365 | 0.919 | 74.2 | 0.975 |